Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India
Copyright © 2016, American Society for Microbiology. All Rights Reserved..
Fluoroquinolones (FQs) are broad-spectrum antibiotics recommended for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients. FQ resistance, caused by mutations in the gyrA and gyrB genes of Mycobacterium tuberculosis, is increasingly reported worldwide; however, information on mutations occurring in strains from the Indian subcontinent is scarce. Hence, in this study, we aimed to characterize mutations in the gyrA and gyrB genes of acid-fast bacillus (AFB) smear-positive sediments or of M. tuberculosis isolates from AFB smear-negative samples from patients in India suspected of having MDR-TB. A total of 152 samples from patients suspected of having MDR-TB were included in the study. One hundred forty-six strains detected in these samples were characterized by sequencing of the gyrA and gyrB genes. The extracted DNA was subjected to successive amplifications using a nested PCR protocol, followed by sequencing. A total of 27 mutations were observed in the gyrA genes of 25 strains, while no mutations were observed in the gyrB genes. The most common mutations occurred at amino acid position 94 (13/27 [48.1%]); of these, the D94G mutation was the most prevalent. The gyrA mutations were significantly associated with patients with rifampin (RIF)-resistant TB. Heterozygosity was seen in 4/27 (14.8%) mutations, suggesting the occurrence of mixed populations with different antimicrobial susceptibilities. A high rate of FQ-resistant mutations (17.1%) was obtained among the isolates of TB patients suspected of having MDR-TB. These observations emphasize the need for accurate and rapid molecular tests for the detection of FQ-resistant mutations at the time of MDR-TB diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Journal of clinical microbiology - 54(2016), 9 vom: 23. Sept., Seite 2298-305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singhal, Ritu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 26.07.2017 Date Revised 15.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/JCM.00670-16 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM261681370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM261681370 | ||
| 003 | DE-627 | ||
| 005 | 20231224200057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/JCM.00670-16 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0872.xml |
| 035 | |a (DE-627)NLM261681370 | ||
| 035 | |a (NLM)27335153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singhal, Ritu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2017 | ||
| 500 | |a Date Revised 15.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016, American Society for Microbiology. All Rights Reserved. | ||
| 520 | |a Fluoroquinolones (FQs) are broad-spectrum antibiotics recommended for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients. FQ resistance, caused by mutations in the gyrA and gyrB genes of Mycobacterium tuberculosis, is increasingly reported worldwide; however, information on mutations occurring in strains from the Indian subcontinent is scarce. Hence, in this study, we aimed to characterize mutations in the gyrA and gyrB genes of acid-fast bacillus (AFB) smear-positive sediments or of M. tuberculosis isolates from AFB smear-negative samples from patients in India suspected of having MDR-TB. A total of 152 samples from patients suspected of having MDR-TB were included in the study. One hundred forty-six strains detected in these samples were characterized by sequencing of the gyrA and gyrB genes. The extracted DNA was subjected to successive amplifications using a nested PCR protocol, followed by sequencing. A total of 27 mutations were observed in the gyrA genes of 25 strains, while no mutations were observed in the gyrB genes. The most common mutations occurred at amino acid position 94 (13/27 [48.1%]); of these, the D94G mutation was the most prevalent. The gyrA mutations were significantly associated with patients with rifampin (RIF)-resistant TB. Heterozygosity was seen in 4/27 (14.8%) mutations, suggesting the occurrence of mixed populations with different antimicrobial susceptibilities. A high rate of FQ-resistant mutations (17.1%) was obtained among the isolates of TB patients suspected of having MDR-TB. These observations emphasize the need for accurate and rapid molecular tests for the detection of FQ-resistant mutations at the time of MDR-TB diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a DNA, Bacterial |2 NLM | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 650 | 7 | |a DNA Gyrase |2 NLM | |
| 650 | 7 | |a EC 5.99.1.3 |2 NLM | |
| 700 | 1 | |a Reynolds, Paul R |e verfasserin |4 aut | |
| 700 | 1 | |a Marola, Jamie L |e verfasserin |4 aut | |
| 700 | 1 | |a Epperson, L Elaine |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Sarin, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Myneedu, Vithal Prasad |e verfasserin |4 aut | |
| 700 | 1 | |a Strong, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Salfinger, Max |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical microbiology |d 1975 |g 54(2016), 9 vom: 23. Sept., Seite 2298-305 |w (DE-627)NLM000005460 |x 1098-660X |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2016 |g number:9 |g day:23 |g month:09 |g pages:2298-305 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/JCM.00670-16 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2016 |e 9 |b 23 |c 09 |h 2298-305 | ||